drugset
drugset / Trial / NCT07298447

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447 ↗

Phase 3 Recruiting 20 enrolled Ionis Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).

Timeline

Start
2026-04-21
Primary completion
2029-06
Completion
2029-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Donidalorsen Antisense oligonucleotide — Subcutaneous

Indications

hereditary angioedema